





**World Dementia
Council** Leading the Global Action
Against Dementia

The dementia landscape project

Research workshop

18 November 2020





Introduction

The World Dementia Council has launched a new global project to review international progress towards the 2025 dementia goals. At the G8 dementia summit in 2013, governments pledged to work together to advance research, improve care, raise awareness and prevent dementia. They committed to make substantial advances by 2025. The Council itself was established following the summit with the aim of supporting and challenging the international community to deliver on their commitments.

In 2021 the Council, with international partners, will hold a summit to bring together the international dementia community to reflect on the progress made towards the 2025 goals. The gathering, consistent with previous World Dementia Council summits, will bring together politicians, policymakers, academia, industry, civil society and people with dementia and their caregivers.

The Council will publish and launch a dementia landscape report at the summit, assessing the advancements that have been made. It will identify how governments, international organizations and the dementia community can help accelerate progress. To help inform the report, in 2020 we are holding a number of global workshops with international experts to reflect on where we have come from, where we are now and what the next steps are to help realize the 2025 goals. The workshops will help the Council prepare the report, drawing on the insight from experts in the field.

Since 2013, through the collective efforts of governments, academia, industry, care providers, research funders, advocates and many others, we have made advances in research, care, awareness and prevention. We are on the path. Our continued collective efforts will help advance the cause. The Council looks forward to hearing from those working across the dementia community as part of this project.




Harry Johns
Chair
World Dementia Council



Lenny Shallcross
Executive Director
World Dementia Council



Welcome



We are excited to invite you to join us at the first-ever virtual World Dementia Council research workshop on 18 November 2020. The world's first G8 dementia summit was held in 2013 in London, where the international community of top scientists in the field, research funders, pharmaceutical companies and governments committed to accelerate the research agenda and deliver the first disease-modifying treatment by 2025. Since then the field has made considerable advances and there has been a significant increase in funding in the field of dementia research. This has been instrumental in fostering global collaborations and driving cutting-edge technological developments, including the use of big data, to understand the biology of dementia and develop potential therapeutics and treatments.

The workshop will cover two themes that we have selected based on their importance in the field. Firstly, early detection and biomarkers. This is an exciting area of progress and also a key one. According to the World Health Organization, around 50 million people have dementia worldwide and this number is projected to reach 152 million in 2050. In 2015, the global societal cost of dementia was estimated to be \$818 billion, and this is projected to rise up to \$2 trillion by 2030. Therefore, it is critical to be able to accurately detect Alzheimer's and all other dementia, and develop and deliver effective treatments by identifying individuals who might most benefit from it. Secondly, the workshop will discuss advances in treatment: what the state of play is and what the challenges are.

We are delighted that Professor Oskar Hansson and Professor Reisa Sperling will give an overview on the first theme, and Dr Catherine Mummery and Dr Eric Siemers on the second. Each will shape their contribution around where we have come from, where the field is now, and outline future steps. At the conclusion of the overview presentations there will be an open discussion. The session will last for 90 minutes. We look forward to having you participate in this exciting workshop.




Dr Maria Carrillo
Chief Scientific Officer
Alzheimer's Association



Professor Philip Scheltens
Director, Alzheimer Center
Amsterdam University Medical Centers



Logistics and agenda




Wednesday 18 November 2020

Virtual meeting

08:00 CST Chicago
09:00 EST New York
14:00 GMT London
15:00 CET Central Europe
19:30 IST New Delhi
23:00 JST Tokyo



Time (all CST)	Section	Speaker(s)
08:00	Welcome and opening remarks	Maria Carrillo Philip Scheltens Lenny Shallcross
08:10	Early detection and biomarkers: opening presentations and opportunity for comments	Oskar Hansson Reisa Sperling
08:30	Advancing treatments: opening presentations and opportunity for comments	Catherine Mummery Eric Siemers
08:50	Open discussion on the key challenges and opportunities to advancing research and treatments	Moderated by chairs
09:25	Closing remarks	Maria Carrillo Philip Scheltens



Co-chairs



Dr Maria Carrillo


Maria Carrillo is chief scientific officer at the Alzheimer's Association (US), setting the strategic vision for the Association's global research program. Dr Carrillo has published extensively on early diagnosis and biomarker standardization efforts, as well as on the global challenges to progress for research in Alzheimer's and dementia. She is a co-author of the "Appropriate Use Criteria for Amyloid Imaging," published by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer's Association. Dr Carrillo earned her PhD from Northwestern University's Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer's brain imaging and risk factors at Rush University Medical Center in Chicago.



Professor Philip Scheltens

Philip Scheltens is professor of cognitive neurology and director of the Alzheimer Center, Amsterdam University Medical Centers (The Netherlands) and member of the World Dementia Council. His main clinical and research interests are Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national principal investigator for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 70 PhD theses have appeared since. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as the chair of its board.





Speakers



Professor Oskar Hansson

Oskar Hansson is a neurology professor at Lund University and serves as a consulting neurologist at Skåne University Hospital (Sweden). During the last 20 years, Professor Hansson has conducted clinical and translational research focusing on the earliest phases of Alzheimer's. He has built a creative and multi-disciplinary research team and leads the Swedish BioFINDER study. His research combines the study of well characterized patient cohorts with state-of-the-art biomedical and biophysical techniques, most notably in brain imaging. Professor Hansson earned his doctorate in neurobiology, his medical degree, and additional training as a neurology specialist at Lund University.



Dr Catherine Mummery


Catherine Mummery is a consultant neurologist at the National Hospital for Neurology and Neurosurgery (UK) specialising in focal cognitive disorders. She completed her medical training at University College Hospital and a PhD in cognitive neurology as an MRC clinical fellow at the Wellcome Department of Cognitive Neurology. Her research interests are in the functional network underlying semantic processing and alteration in patients using multimodal techniques including functional imaging.



Dr Eric Siemers

Eric Siemers has over 25 years of experience in clinical trials of neurodegenerative disease. His research focus is on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases. Dr Siemers most recently served as a distinguished medical fellow for Eli Lilly and Company's Alzheimer's Disease Global Development Team, where he was responsible for the design and implementation of five large phase


III clinical studies, in addition to playing a major collaborative role in two public-private partnership studies. Dr Siemers earned his medical degree from the Indiana University School of Medicine (US).



Professor Reisa Sperling

Reisa Sperling is co-principal investigator of the Harvard Aging Brain Study in Boston (US). She is a neurologist focused on the detection and treatment of Alzheimer’s disease, even before clinical symptoms are evident. Her research uses neuroimaging and cognitive tests to understand the aging brain and the earliest changes associated with Alzheimer’s disease. She is a professor in neurology at Harvard Medical School, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, and director of neuroimaging for the Massachusetts ADRC at Massachusetts General Hospital.





Project overview

2021 dementia landscape summit and report

The Council – with international partners – will hold a summit in 2021 bringing together the global dementia community to reflect on the progress made towards the 2025 goals and to assess the challenges that remain. The UK hosted the first dementia summit as part of their G8 presidency in 2013, and this summit will coincide with the UK's G7 presidency in 2021. The convening, consistent with previous World Dementia Council summits, will gather politicians, policymakers, academia, industry, civil society and people with dementia and their caregivers.




The first dementia summit in London, part of the UK's G8 presidency in 2013



The 2018 World Dementia Council summit in London



Dutch health minister Hugo de Jonge addresses attendees of the 2019 World Dementia Council summit in Tokyo



The summit themes will reflect those in the 2013 G8 communique: research, care, prevention/risk reduction and awareness. At the summit we will launch the dementia landscape report that will reflect on the progress made globally and make recommendations on how the international community can accelerate progress towards the 2025 goals.

Workshops and roundtables

To inform the dementia landscape report, the Council is hosting three virtual workshops for international dementia leaders focusing on key themes that were identified at the London dementia summit in 2013. The workshops will be on:

- Research
- Care
- Prevention/risk reduction

In addition the Council will host smaller roundtables that will focus on key themes and new policy priorities that we have agreed to highlight in the report. These themes include data sharing, technology in the health and social care sector, and the impact of dementia on low- and middle-income countries.



A 2019 roundtable event held in Los Angeles, as part of the World Dementia Council's dementia friendly initiatives project



The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

worlddementiacouncil.org

© 2020 World Dementia Council
UK charity registration number: 1170743

Cover image editorial credit: Shutterstock.com

